AMGEN PRESENTS NEW AMG 133 PHASE 1 CLINICAL DATA AT WCIRDC 2

/PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced new Phase 1 data from AMG 133, a novel bispecific glucose-dependent insulinotropic polypeptide receptor...

Related Keywords

Puerto Rico , United States , America , American , Jessica Akopyan , Davidm Reese , Prevalence Estimates For Selected Health Outcomes , Instagram , Amgen , National Health , Linkedin , Twitter , National Health Statistics , Public Health , Therapeutics Inc , Prepandemic Data Files Development Of , Teneobio Inc , Nutrition Examination , Nutrition Examination Survey , Centers For Disease , Kyowa Kirin Co Ltd , World Health Organization , Most Sustainable Companies , Beigene Ltd , Exchange Commission , Youtube , American Medical Association , World Congress , European Health Commission , Chemocentryx Inc , Body Weight , Highest Dose After , Insulin Resistance , Cardiovascular Disease , Body Mass Index , Dow Jones Industrial Average , Five Prime Therapeutics , Data Files Development , Prevalence Estimates , Selected Health , National Health Statistics Reports , Disease Control , Accessed November , Silver Spring , Multiple Ascending Dose Study , Participants With ,